A Phase 2 Clinical Trial for the Treatment of Moderate to Severe Inflammatory Rosacea with its Proprietary Minocycline Topical Gel
Frankfurt expo showcases a transformation in contract R&D and manufacturing of drug ingredients.
The pharmaceutical chemical sector is experiencing a prolonged period of profitability and a wave of transformation as companies invest profits in new ventures and new capacity. A picture of how the sector is evolving came into focus last month when CPhI Worldwide, the annual pharmaceutical ingredients exhibition, came to Frankfurt.
The event—the largest of its kind in the world, attended by more than 40,000 people—followed a year and a half of robust merger and acquisition . . .